So-Fong Wong
Family · Pasadena, TXNPI 1043290703
Payments from drug & device makers
Across 354 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Bayer$1K
- Lilly USA, LLC$844
- AbbVie$662
- Novartis$476
- plus $3K from 30 others
What the payments were for
- Food & beverage$9,289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $1,740 |
| Novo Nordisk | 56 | $1,421 |
| Bayer | 36 | $1,011 |
| Lilly USA, LLC | 27 | $844 |
| AbbVie | 34 | $662 |
| Novartis | 31 | $476 |
| Amgen | 12 | $459 |
| Johnson & Johnson | 10 | $387 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $328 |
| Exact Sciences | 12 | $224 |
| Pfizer | 10 | $173 |
| Astellas Pharma US Inc | 8 | $154 |
| Amarin Pharma, Inc. | 7 | $148 |
| Teva Pharmaceuticals USA, Inc. | 6 | $141 |
| Xeris Pharmaceuticals, Inc. | 8 | $123 |
| Pulmonx Corporation | 1 | $118 |
| GSK | 5 | $103 |
| Boehringer Ingelheim | 6 | $88 |
| Sanofi-aventis U.S. LLC | 4 | $87 |
| Almatica Pharma LLC | 4 | $78 |
| Heartflow, Inc. | 2 | $66 |
| Inspire Medical Systems, Inc. | 3 | $63 |
| Phathom Pharmaceuticals, Inc. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Abbott | 2 | $43 |
| Biogen | 2 | $36 |
| Scilex Pharmaceuticals Inc. | 2 | $29 |
| Philips North America LLC | 2 | $29 |
| Medtronic | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Insulet Corporation | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$478
- BREZTRI$471
- FARXIGA$422
- MOUNJARO$337
- Ozempic$250
- XARELTO$248
- AIRSUPRA$222
- Creon$125
- Otezla$123
- Repatha$122
- ZEPBOUND$122
- CHARTIS CATHETER$118
- ZEPHYR DELIVERY CATHETER$118
- ZEPHYR ENDOBRONCHIAL VALVE$118
- PULMONX CHARTIS TABLET CONSOLE$118
How this compares
$9,289 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $36,197 |
| JardianceEmpagliflozin | 27 | $33,380 |
| TrulicityDulaglutide | 11 | $21,814 |
| Bydureon BciseExenatide Microspheres | 13 | $20,931 |
| FarxigaDapagliflozin Propanediol | 20 | $16,312 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $14,397 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $12,522 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $6,884 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $4,435 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $3,148 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $2,602 |
| Losartan Potassium | 125 | $1,876 |
| Raloxifene Hcl | 37 | $1,680 |
| Atorvastatin Calcium | 171 | $1,350 |
| Levothyroxine Sodium | 149 | $1,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,421 | $36,19731 claims |
| Boehringer IngelheimJardiance | $88 | $33,38027 claims |
| Lilly USA, LLCTrulicity | $844 | $21,81411 claims |
| AstraZenecaFarxiga | $1,740 | $16,31220 claims |
| AbbVieSynthroid | $662 | $73927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Pasadena
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.